Background: Cornelia de Lange Syndrome (CdLS) is a rare but severe clinically heterogeneous developmental disorder characterized by facial dysmorphia, growth and cognitive retardation, and abnormalities of limb development. Objectives: To determine the pathogenesis of a patient with CdLS. Methods: We studied a patient with CdLS by whole exome sequencing, karyotyping and Agilent CGH Array. The results were confirmed by quantitative real-time PCR analysis of the patient and her parents. Further comparison of our patient and cases with partially overlapping deletions retrieved from the literature and databases was undertaken. Results: Whole exome sequencing had excluded the mutation of cohesion genes such as NIPBL, SMC1A and SMC3. The result of karyotyping showed a deletion of chromosome 9q31.1-q32 and the result of Agilent CGH Array further displayed a 12.01-Mb region of deletion at chromosome bands 9q31.1-q32. Reported cases with the deletion of 9q31.1-q32 share similar features with our CdLS patient. One of the genes in the deleted region, SMC2, belongs to the Structural Maintenance of Chromosomes (SMC) family and regulates gene expression and DNA repair. Conclusions: Patients carrying the deletion of 9q31.1-q32 showed similar phenotypes with CdLS.
Introduction
Cornelia de Lange Syndrome (CdLS), also known as Brachman de Lange syndrome, is a rare but severe clinically heterogeneous developmental disorder characterized by distinctive facial features, growth and cognitive retardation, and abnormalities of limb development [1] . The facial features are the most clinically consistent and recognizable characteristics of CdLS, including underdeveloped orbital arches, long curly eyelashes, thin lips, downturned angle of the mouth, hirsutism, short neck with low anterior and posterior hairlines, anteverted nares, well defined and arched (pencil-like) eyebrows, and long philtrum [2] . The incidence of CdLS varies from 1/10,000 to 1/60,000 of live births. However, due to possibly misdiagnosed cases, the exact incidence is still unclear [3] .
Approximately 60% of CdLS patients carried mutations in NIPBL, 5% of CdLS patients had mutations in SMC1A, and one individual was found to have a deletion in SMC3. The haploinsufficient mutations of NIPBL (such as nonsense mutations, splice site mutations, and out-of-frame deletions or insertions) usually result in a more severe growth and cognitive retardation, as well as abnormalities of limb development. However, patients with mutations in SMC1A and SMC3 only have mild or moderate phenotypes without distinct impairments or structural abnormalities of the limb or other organ systems [4] . Most genes associated with CdLS patients, including NIPBL, SMC1A and SMC3, are cohesin related genes. Studies of other genes, such as MRPS22 and HDAC8, and an 8p23.1 deletion are ongoing [5] [6] [7] .
To date, approximately 35% of clinically diagnosed CdLS patients do not carry any identifiable mutation, which indicates that some disease-related genes remain to be discovered. In this study, we analyzed via whole exome sequencing, karyotyping and aCGH the genetics of an 18-month-old female CdLS patient with facial dysmorphism, mental retardation, developmental delay, a small atrial septal defect (ASD), hearing disorder, and irregular dentition. After excluding the mutations of these cohesion genes by whole exome sequencing, we detected a 12.01 Mb deletion in 9q31.1-q32 which may be associated with CdLS. After a comparison of our case with 11 previously reported cases with partially overlapping deletions, we found that all of these cases shared many features with CdLS, which indicated that they might have a common pathogenesis that caused these features. Thus we suggest that some genes in 9q31.1-q32 may be associated with these common features and may be candidate genes in the cohort of CdLS patients in whose DNA no mutation of known pathogenic genes has yet been discovered.
Materials and Methods

Whole Exome Sequencing
Genomic DNA was fragmented and hybridized to the capture array according to the manufacturer's protocol of QIAamp DNA Blood Midi Kit, and the enriched DNA fragments were eluted and amplified with ligation-mediated PCR through the linkers added to the exonic DNA fragments. Before the second run of library construction, qPCR was performed to estimate the degree of enrichment of the exonic sequences. A minimum requirement of an 80-fold enrichment was achieved for all of the libraries prepared for the next procedure. The enriched exonic DNA fragments were randomly blunt-end ligated with DNA ligase to fragments ranging in size from 2-5 kb. The resultant DNA products were sheared to 200 bp on average and were subjected to standard Illumina hiseq2500 library preparation according to the Illumina protocol.
Exome-enriched shotgun libraries were sequenced on the Illumina HiSeq 2500 platform, and paired-end reads with an average size of 100 bp were generated. Image analysis and base calling were performed with the Illumina's Consensus Assessment of Sequence and Variation (CASAVA) 1.8, using default parameters. After removing reads with sequence matching the sequencing adaptors and low-quality reads with more than five unknown bases, high-quality reads were aligned to the NCBI human reference genome (hg19) using Burrows-Wheeler Aligner (BWA) version 0.6.2 [8] with the default parameters. To identify potential mutations, we performed local realignments of the BWA reads using the Genome Analysis Toolkit (GATK) [9] . Mutations including nonsynonymous mutations, stopgain mutations, stoploss mutations, splice
Karyotyping
The karyotypes were examined by G-banding at the level of 550. The peripheral blood samples were collected with heparin added as an anticoagulant from the patient and parents and cultured in RPMI1640 culture medium with 20% calf serum (Invitrogen Gibco, USA) at 37°C in 5% CO2. Preparation of metaphase and conventional cytogenetics followed standard laboratory procedures. At least 20 banded metaphases with good chromosome separation were analyzed by experienced geneticists. Commercially available locusspecific probe kits N25 (D22S75) and TUPLE1 (HIRA) were purchased from Vysis (Downers Grove, IL, USA).
Agilent CGH Array 4×180K
Peripheral blood samples were exsanguinated into an EDTA anticoagulant tube. DNA was extracted with the QIAamp DNA Blood Midi Kit (Qiagen, Duesseldorf, Germany) following the manufacturer's instructions. Purified genomic DNA was resuspended in ddH2O for SNP-array analysis or in Tris-EDTA for other experiments, and DNA stocks were stored at -80℃. Whole-genome aCGH was performed on the patient's blood using an Agilent CGH Array 4×180K, which has 170,334 probes and a median resolution of 13 kb across the entire genome according to the manufacturer's instruction. The sample passed initial QC and was submitted for copy number various (CNV) discovery. High-confidence CNVs were detected by ADM-2 with the minimum marker 5 and threshold 6.0. The data was filtered, and only those regions larger than 100 kb comprising at least 50 contiguous markers were retained. The details of this experiment were deposited in dbVar (http://www.ncbi.nlm.nih.gov/dbvar) and the accession number is GSE54354 (NCBI GEO). Finally, the results were compared to known CNVs in the Database of Genomic Variants (DGV, http:// dgvbeta.tcag.ca/dgv/app/home) and Online Mendelian Inheritance in Man (OMIM, http://www.ncbi.nlm. nih.gov/omim/) to distinguish common CNVs from CNVs likely to be causal.
qPCR Validation
For each tested CNV, at least three primer pairs in three genes were designed within the boundaries of the CNV region (Table 1) . Small portions of genomic DNA extracted from healthy people were mixed to form a DNA pool serving as the normal control, while the gene ALB, which has few variations, was used as the control gene in qPCR. These genes were quantified to determine the copy number (CN), as were pivotal genes nearby. When results differed between aCGH and qPCR, the qPCR results were used. When the results were consistent, the segments were further validated in the patient's parents.
Results
Clinical description
The child was diagnosed with CdLS when she was eighteen months old. Now, she is two years old. She is the only child in the family, and there is no family history of congenital malformations. Her mother was 18 years old and her father was 20 years old at her birth, and her parents are non-consanguineous. At 41 weeks of gestation, she was born with a dyspnea and distinctive facial features (a large protruding left ear, underdeveloped orbital arches, long curly eyelashes, thin lips, downturned angle of the mouth, short neck with low anterior and posterior hairlines, anteverted nares, well defined and arched eyebrows, long philtrum, anterior median fissure and micrognathia) (see Fig. 1 ). She was born by a cesarean section delivery due to oligohydramnios and lived in the newborn ICU for 15 days. Her birth weight was 1300g (a very low birth weight for infants), and her birth length was 48 cm. At the age of 1 month, she was diagnosed with ASD (see Fig. 2 ). Then, she grew up with obvious development delay. She could raise her head when she was 5 months old, sit at 10 months and now she still can't walk or speak. She is always aggressive and hard to communicate Fig. 4 ), and the deletion of 8p23.1 was not discovered. The deleted region encompasses 22 OMIM genes including SMC2, a member of Structural Maintenance of Chromosomes (SMC) family. Then the deletion of 9q31.1-q32 was confirmed in the child by qPCR, while her parents did not have this deletion.
Discussion
Our patient is an 18-month-old female CdLS patient with facial dysmorphism, mental retardation, developmental delay, a small ASD, hearing disorder, and irregular dentition. In order to study the probable pathogenesis of this CdLS patient, we first studied the CdLS patient by whole exome sequencing. However, there was no mutation of previously-shown related genes such as NIPBL, SMC1A, SMC3, MRPS22 and HDAC8. Thus, there still must be 
Patients with deletion of 9q31.1-q32 showed similar features with CdLS
CdLS is characterized by distinctive facial features, growth and cognitive retardation, and abnormalities of limb development. While growth and cognitive retardation are common features of many syndromes, the distinctive facial features and limb development abnormalities play key roles in the diagnosis. Research in the USA showed that an average of 75% of cases was correctly diagnosed by only facial photographs. The emphasis was placed on eyebrows and nasal features. Upper lip and micrognathia were also important characteristics [2] .
Karyotyping and Agilent CGH Array analysis showed that the patient with CdLS carried a deletion of 9q31.1-q32. However, reports about the deletion of chromosome 9q are rare and only about 20 patients have been described in medical literature, spanning the breakpoints from 9q21 to 9q34 [10] . To date, no well-defined syndrome has been specifically associated with this region. A comparison of our patient with the 11 previously reported cases with partially overlapping deletions is provided in Table 2 and their deletion regions are compared in Fig. 5 (case 1 and case 4 came from DECIPHER, http://decipher.sanger.ac.uk/) [10] [11] [12] [13] [14] [15] [16] .
It's interesting to note that the phenotypes of most patients carrying a deleted region overlapping with our proband have similar features including postnatal growth retardation, intellectual disability, craniofacial anomalies, and limb abnormalities (see Table 2 ). Nearly all phenotypes are those of CdLS, except neoplasm of the skin, which is rare in CdLS. Both case 4 and case 10 have this phenotype. After reviewing genes in the deleted region of case 4, case 10, we found a gene PTCH1 (located in chr9:98247867-98279247). Mutations of PTCH1 have been identified to be responsible for nevoid basal cell nevus syndrome (NBCCS) in many cases [17] [18] [19] . Both haploinsufficiency and duplication of PTCH1 could cause NBCCS [20, 21] . Therefore, we deduced that maybe PTCH1, which is not in our deletion region, was the cause of neoplasm of the skin. Though it's inadequate to say that the 11 cases are completely in accordance with the diagnostic criteria of CdLS, it's true that they share similar phenotypes with CdLS.
Candidate genes for these common phenotypes or CdLS in 9q31.1-q32
To date, no well-defined syndrome has been specifically associated with 9q31.1-q32 and no part of the deletion region is shared by all the cases. It's very difficult to correlate these phenotypes with specific genes in such a large microdeletion. Fortunately, these phenotypes are similar to those of CdLS. Maybe some genes that have not been reported are associated with CdLS or these common features. Keeping this in mind, we first analyzed the pathogenesis that had been widely accepted in CdLS and tried to find some candidate genes.
SMC2. SMC1A, SMC2 and SMC3 are members of the SMC family. The SMC proteins share highly similar domain structures. SMC2 and SMC4 constitute the condensin complexes, which have structures exactly like that of the SMC1/3 cohesin complex: a V-shaped structure with two long coiled-coil arms, each containing an ATP-binding cassette (ABC) head domain at the distal end [22] . Mutations in SMC1A and SMC3 had been identified in CdLS patients with mild or moderate phenotypes. SMC1A and SMC3 are essential for regulating gene expression, DNA repair and sister chromatid cohesion [23] . In mammals, cohesin including SMC1A and SMC3 accumulate at sites where CCCTC-binding factor (CTCF) is localized [24] . Knockdown of cohesin alone resulted in deregulated gene expression among CTCF targets [25] . These studies indicated that the phenotypes of CdLS may be due to defects in the function of cohesin and CTCF in regulating gene activities [26] [27] [28] [29] .
The functions of SMC2 and SMC1A, SMC3 are highly similar and related. SMC2 play key roles in DNA repair and correct progression during mitosis. Condensin could act against replication protein A in mitosis and interphase by promoting DNA annealing [30] . The mutation in the hinge domain of SMC2 resulted in severely reduced viability during mitosis after exposure to DNA damaging agents at permissive temperatures. Besides, SMC2 is required for the correct progression of sister chromatid cohesion [31] .
Previous studies confirmed the role of SMC2 in gene regulation [32, 33] . More recently, it has been discovered that SMC2 can negatively regulate rRNA gene transcription via CTCF, which is colocalized with and required for cohesin. SMC2 and CTCF bind to a specific rDNA locus in a competitive manner. SMC2 knockdown promotes the loading of CTCF onto the rDNA locus and facilitates CTCF-enhanced rRNA gene transcription [34] . While the severe phenotypes of CdLS are related with the defect in cohesin function of regulating gene expression by CTCF, SMC2 can regulate gene transcription by CTCF. These findings indicate that SMC2 may cause CdLS via the defect in regulating CTCF-associated gene expression and DNA repair.
DFNB31. There is no relationship between DFNB31 and function of gene regulation or DNA repair. DFNB31, which is located in 9q31.2, is a gene responsible for autosomal recessive non-syndromic hearing loss (ARNSHL) [35] . ARNSHL is the most common and severe form of hereditary hearing impairment, accounting for approximately 80% of cases of genetic deafness. However, in CdLS patients, hearing loss is perceived as an atypical feature. About 40-80% of cases may carry this phenotype [2] . Our patient was diagnosed with hearing disorder at the age of 17 months. Thus, it's a question whether deafness is a part of CdLS or another disease apart from CdLS. As ARNSHL is an autosomal recessive genetic disease and there is one chromosome microdeletion in our patient, so if the hearing disorder were caused by ARNSHL, there must be a mutation of the DFNB31 in the other chromosome [36] . Keeping this in mind, we searched for the mutations of DFNB31 in our patient. However, the result of whole exome sequencing showed that there was no functional mutation of DFNB31 in this patient. Consistent with the incidence of hearing loss in CdLS, in all 12 patients we have described above, there are five (41.7%) patients suffering from deafness. Among these five patients, only two cases' deletion region contained the gene DFNB31. Thus, maybe the hearing disorder of these patients was a part of CdLS, but not due to DFNB31.
Other genes. SMC2 haploinsufficiency may play a role in the occurrence of some clinical features in this patient. Only 6 cases have the deletion of SMC2 (Fig. 5) and there is no specific phenotype in patients with SMC2. Thus, there still must be some other genes that contribute to these phenotypes. The functions of genes in chr9:98247867-98279247 need to be further studied.
Conclusion
In our study, we first excluded the mutations of CdLS related genes which had been reported previously such as NIPBL, SMC1A, SMC3, MRPS22 and HDAC8. Then, we detected a 12.01-Mb deletion at chromosome band 9q31.1-q32 by karyotyping and aCGH array. The comparison of our patient with 11 previously reported cases with partially overlapping deletions showed similar phenotypes and almost all phenotypes are similar to those of CdLS. Gene SMC2 may play key roles in CdLS or these common phenotypes by influencing the function of gene expression and DNA repair. However, with access to only one patient, we cannot verify the role of the 12.01-Mb deletion at chromosome band 9q31.1-q32 and the function of SMC2 among a larger population of CdLS patients, so further studies should be performed.
Ethics Statement
Ethics committee of Xinhua Hospital specifically approved of this study and written informed consents were obtained from her parents. The parents of the individual in this manuscript have given written informed consent to publishing these case details.
